This episode of the LongeCity interview podcast features Reason, founder of Fight Aging and co-founder of Repair Biotechnologies, discussing innovative approaches to reversing heart disease and insights on progress toward tackling biological ageing.

Key Points:

Reason emphasizes that while the path to biological rejuvenation is complex, innovative therapies like Repair Biotechnologies' cholesterol-degrading platform are leading us toward impactful treatments. With continued support and funding, the future holds potential for these therapies to enter mainstream medicine by the next decade.

• Founding Repair Biotechnologies: Reason shares the origins of Repair Biotechnologies, co-founded with Bill Chairman, driven by the goal of accelerating progress in heart disease therapies.
• Cholesterol-Degrading Platform: Repair Biotechnologies developed a unique gene therapy targeting cholesterol in the liver to reverse atherosclerosis (plaque build-up in arteries), which has shown promising results in animal models.
• Role of the Liver in Cholesterol Management: Their therapy focuses on lowering free cholesterol in the liver, prompting the liver to reduce cholesterol throughout the body, which leads to plaque regression in arteries.
• Transition to Lipid Nanoparticle Delivery: The company shifted from AAV vectors to lipid nanoparticles for safer and more targeted delivery of their gene therapy, especially since high-dose AAV had adverse effects.
• Challenges in Longevity Research: Reason reflects on the slow but steady progress in rejuvenation therapies, noting that mainstream adoption will take time, but promising signs are emerging.
• Outlook for Clinical Trials: Repair Biotechnologies aims to start human clinical trials by 2026, targeting a rare disease as a pathway to broader applications in cardiovascular health.